Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of STN1014003 ophthalmic solution in healthy male adults
jRCT2051250132Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sepetaprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Plasma pharmacokinetics. Started Nov 2025; status: completed.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2051250132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250132.